BofA analyst Adam Ron downgraded Privia Health to Neutral from Buy with a $21 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRVA:
- Evercore says Apollo deal ‘doesn’t sound like a big risk’ to Privia
- Privia Health Appoints Edward C. Fargis as General Counsel
- Privia Health appoints Fargis as General Counsel
- Privia Health to Report Fourth Quarter and Full-Year 2023 Results on Tuesday, February 27
Questions or Comments about the article? Write to editor@tipranks.com